Ionis Expands its Collaboration with Novartis to Advance Next Generation Program Targeting Lp(a) for Cardiovascular Disease
Shots:
- The companies have decided to expand their 2017 collaboration for the discovery, development & commercialization of a novel medicine for patients with lipoprotein(a), or Lp(a)-driven CVD. The recent collaboration will use Ionis' advancing RNA-targeting platform technologies to deliver a novel Lp(a)-targeting therapy
- Under the terms of the agreement, Ionis will receive $60M up front & is eligible to receive development, regulatory and commercial milestones along with royalties. Novartis will lead the development, manufacturing & commercialization of the next-generation Lp(a) therapy
- The previous collaboration focused on the development & commercialization of pelacarsen, currently being studied in the P-III study (HORIZON) conducted by Novartis & results are expected in 2025
Ref: PR Newswire | Image: Ionis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
